Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

515
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
515

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cenobamate: A Review in Focal-Onset Seizures.

CNS drugs·2025
Same author

Ozanimod: A Review in Relapsing Forms of Multiple Sclerosis.

CNS drugs·2024
Same author

Bimekizumab: A Review in Psoriatic Arthritis.

Drugs·2024
Same author

Correction: Eplontersen: First Approval.

Drugs·2024
Same author

Eplontersen: First Approval.

Drugs·2024
Same author

Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis.

Drugs·2023

Related Experiment Video

Updated: Jun 25, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K

Talicabtagene Autoleucel: First Approval.

Tina Nie1

  • 1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. mdt@adis.com.

Molecular Diagnosis & Therapy
|May 23, 2024
PubMed
Summary

Talicabtagene autoleucel, a CAR T-cell therapy, shows high response rates in relapsed/refractory B-cell malignancies. This therapy received approval in India for B-cell lymphomas and acute lymphoblastic leukemia.

Area of Science:

  • Oncology
  • Immunotherapy
  • Cellular Therapy

Background:

  • Relapsed/refractory B-cell malignancies present significant treatment challenges.
  • Chimeric antigen receptor (CAR) T-cell therapy offers a novel approach for these hematological cancers.

Purpose of the Study:

  • To summarize the development milestones of talicabtagene autoleucel.
  • To highlight its recent approval for specific B-cell malignancies in India.

Main Methods:

  • Development of talicabtagene autoleucel, a CAR T-cell therapy using autologous T cells engineered with a humanized anti-CD19 CAR.
  • Pooled analysis of Phase I and Phase II clinical trial data.

Main Results:

  • Talicabtagene autoleucel demonstrated high response rates in patients with relapsed/refractory B-cell malignancies.

More Related Videos

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

488

Related Experiment Videos

Last Updated: Jun 25, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

488
  • A single intravenous dose was effective in the studied patient population.

    • Conclusions:

    • Talicabtagene autoleucel represents a significant advancement in treating relapsed/refractory B-cell malignancies.
    • The therapy's approval in India marks a key milestone for CAR T-cell treatments in the region.